Cargando…
Alpelisib-Induced Diabetic Ketoacidosis in a Non-diabetic Patient
Alpelisib is a phosphoinositol-3-kinase alpha catalytic subunit (PIK3CA) inhibitor used in patients with PIK3CA mutated breast cancer. The phosphatidylinositol 3-kinase (PI3K) pathway is responsible for activating protein kinase-B (AKT), and activated AKT promotes translation of glucose transporter...
Autores principales: | Fugere, Tyler, Roy, Arya Mariam, Makhoul, Issam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648282/ https://www.ncbi.nlm.nih.gov/pubmed/34900474 http://dx.doi.org/10.7759/cureus.19295 |
Ejemplares similares
-
Alpelisib-Induced Diabetic Ketoacidosis
por: Nguyen, Paul, et al.
Publicado: (2021) -
Alpelisib-Induced Diabetic Ketoacidosis in a Patient With Metastatic Breast Cancer
por: Al Zeyoudi, Jawaher, et al.
Publicado: (2021) -
Alpelisib-Induced Diabetic Ketoacidosis in a Patient With Metastatic Breast Cancer
por: Abufaied, Mohamad, et al.
Publicado: (2021) -
Alpelisib-Induced Diabetic Ketoacidosis
por: Espinosa, Luis Borges, et al.
Publicado: (2021) -
Diabetic Ketoacidosis With Alpelisib
por: Jeun, Rebecca, et al.
Publicado: (2021)